Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2024

Open Access 01-12-2024 | Atrial Fibrillation | Research

Association between baseline glycated hemoglobin level and atrial fibrillation recurrence following cryoballoon ablation among patients with and without diabetes

Authors: Zheng Chen, Ruixin Zhang, Xinlin Zhang, Wei Xu

Published in: BMC Cardiovascular Disorders | Issue 1/2024

Login to get access

Abstract

Objectives

The study aims to assess the effect of baseline glycated hemoglobin (HbA1c) levels on atrial fibrillation (AF) recurrence following cryoballoon ablation in patients with and without diabetes.

Methods

Consecutive AF patients receiving first cryoballoon ablation between April 2018 and April 2021 were included. AF recurrence and other clinical outcomes were recorded for a minimum of 12 months post-ablation, with regular assessments at 3, 6, and 12 months, followed by annual check-ups. The primary outcome was AF recurrence after ablation at longest follow-up. Multivariate Cox proportional hazards regression models were utilized to calculate the hazard ratio (HR) and 95% CI per standard deviation (SD) increase of baseline HbA1c level.

Results

335 patients were included in the analysis. The mean age was 61.7 years, 61.8% were male. 12.8% had type 2 diabetes, and 81.7% of patients had paroxysmal AF. The median level of HbA1c was 5.3%, and the mean CHA2DS2-VASc score was 1.8. All cryoballoon ablation procedures, utilizing a 28-mm balloon, achieved successful pulmonary vein isolation. Over a median follow-up of 18 months, 105 patients (31.3%) experienced AF recurrence. In multivariate Cox proportional hazards analysis, a higher HbA1c level, persistent AF (HR 1.91, 95% CI 1.08 to 3.39, P = 0.026), alcohol consumption (HR 2.67, 95% CI 1.33 to 5.37, P = 0.006), and Nadir RSPV (HR 1.04, 95% CI 1.00 to 1.08, P = 0.005) were significant predictors of AF recurrence. Per-SD increase of HbA1c was associated with a 1.75-fold increase risk of AF recurrence (HR 1.75, 95% CI 1.39 to 2.21, P < 0.001). Subgroup analysis revealed that a higher HbA1c level was associated with a higher risk of AF recurrence in patients with and without diabetes, and in patients with paroxysmal and persistent AF.

Conclusion

Baseline HbA1c level was an independent predictor of AF recurrence following cryoablation, both in patients with and without diabetes.
Literature
1.
go back to reference Li L-H, Sheng C-S, Hu B-C, Huang Q-F, Zeng W-F, Li G-L, et al. The prevalence, incidence, management and risks of atrial fibrillation in an elderly Chinese population: a prospective study. BMC Cardiovasc Disord. 2015;15:31.CrossRefPubMedPubMedCentral Li L-H, Sheng C-S, Hu B-C, Huang Q-F, Zeng W-F, Li G-L, et al. The prevalence, incidence, management and risks of atrial fibrillation in an elderly Chinese population: a prospective study. BMC Cardiovasc Disord. 2015;15:31.CrossRefPubMedPubMedCentral
2.
go back to reference Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of Atrial Fibrillation. J Am Coll Cardiol. 2014;64:281–9.CrossRefPubMed Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of Atrial Fibrillation. J Am Coll Cardiol. 2014;64:281–9.CrossRefPubMed
3.
go back to reference Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, et al. Impact of CARDIOrespiratory FITness on Arrhythmia recurrence in obese individuals with Atrial Fibrillation. J Am Coll Cardiol. 2015;66:985–96.CrossRefPubMed Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, et al. Impact of CARDIOrespiratory FITness on Arrhythmia recurrence in obese individuals with Atrial Fibrillation. J Am Coll Cardiol. 2015;66:985–96.CrossRefPubMed
4.
go back to reference Staerk L, Wang B, Preis SR, Larson MG, Lubitz SA, Ellinor PT et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ. 2018:k1453. Staerk L, Wang B, Preis SR, Larson MG, Lubitz SA, Ellinor PT et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ. 2018:k1453.
5.
go back to reference Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. Framingham Heart Study JAMA. 1994;271:840–4.PubMed Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. Framingham Heart Study JAMA. 1994;271:840–4.PubMed
6.
go back to reference Fernandes GC, Fernandes A, Cardoso R, Penalver J, Knijnik L, Mitrani RD, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021;18:1098–105.CrossRefPubMed Fernandes GC, Fernandes A, Cardoso R, Penalver J, Knijnik L, Mitrani RD, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021;18:1098–105.CrossRefPubMed
7.
go back to reference Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, et al. Effect of Dapagliflozin on Atrial Fibrillation in patients with type 2 diabetes Mellitus: insights from the DECLARE-TIMI 58 Trial. Circulation. 2020;141:1227–34.CrossRefPubMed Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, et al. Effect of Dapagliflozin on Atrial Fibrillation in patients with type 2 diabetes Mellitus: insights from the DECLARE-TIMI 58 Trial. Circulation. 2020;141:1227–34.CrossRefPubMed
8.
go back to reference Zhao A, Squara F, Marijon E, Thomas O. Two-year clinical outcome after a single cryoballoon ablation procedure: a comparison of first- and second-generation cryoballoons. Arch Cardiovasc Dis. 2017;110:543–9.CrossRefPubMed Zhao A, Squara F, Marijon E, Thomas O. Two-year clinical outcome after a single cryoballoon ablation procedure: a comparison of first- and second-generation cryoballoons. Arch Cardiovasc Dis. 2017;110:543–9.CrossRefPubMed
9.
go back to reference Chierchia GB, Namdar M, Sarkozy A, Sorgente A, de Asmundis C, Casado-Arroyo R, et al. Verification of pulmonary vein isolation during single transseptal cryoballoon ablation: a comparison between the classical circular mapping catheter and the inner lumen mapping catheter. Europace. 2012;14:1708–14.CrossRefPubMed Chierchia GB, Namdar M, Sarkozy A, Sorgente A, de Asmundis C, Casado-Arroyo R, et al. Verification of pulmonary vein isolation during single transseptal cryoballoon ablation: a comparison between the classical circular mapping catheter and the inner lumen mapping catheter. Europace. 2012;14:1708–14.CrossRefPubMed
10.
go back to reference Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP et al. Heart Disease and Stroke Statistics—2019 update: a Report from the American Heart Association. Circulation. 2019;139. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP et al. Heart Disease and Stroke Statistics—2019 update: a Report from the American Heart Association. Circulation. 2019;139.
11.
go back to reference Echouffo-Tcheugui JB, Shrader P, Thomas L, Gersh BJ, Kowey PR, Mahaffey KW, et al. Care patterns and outcomes in Atrial Fibrillation patients with and without diabetes. J Am Coll Cardiol. 2017;70:1325–35.CrossRefPubMed Echouffo-Tcheugui JB, Shrader P, Thomas L, Gersh BJ, Kowey PR, Mahaffey KW, et al. Care patterns and outcomes in Atrial Fibrillation patients with and without diabetes. J Am Coll Cardiol. 2017;70:1325–35.CrossRefPubMed
12.
go back to reference Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, et al. Diabetes Mellitus, Glycemic Control, and risk of Atrial Fibrillation. J Gen Intern Med. 2010;25:853–8.CrossRefPubMedPubMedCentral Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, et al. Diabetes Mellitus, Glycemic Control, and risk of Atrial Fibrillation. J Gen Intern Med. 2010;25:853–8.CrossRefPubMedPubMedCentral
13.
go back to reference Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case–control studies of type 2 diabetes Mellitus and Risk of Atrial Fibrillation. Am J Cardiol. 2011;108:56–62.CrossRefPubMedPubMedCentral Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case–control studies of type 2 diabetes Mellitus and Risk of Atrial Fibrillation. Am J Cardiol. 2011;108:56–62.CrossRefPubMedPubMedCentral
14.
go back to reference Qi W, Zhang N, Korantzopoulos P, Letsas KP, Cheng M, Di F, et al. Serum glycated hemoglobin level as a predictor of atrial fibrillation: a systematic review with meta-analysis and meta-regression. PLoS ONE. 2017;12:e0170955.CrossRefPubMedPubMedCentral Qi W, Zhang N, Korantzopoulos P, Letsas KP, Cheng M, Di F, et al. Serum glycated hemoglobin level as a predictor of atrial fibrillation: a systematic review with meta-analysis and meta-regression. PLoS ONE. 2017;12:e0170955.CrossRefPubMedPubMedCentral
15.
go back to reference Zhao H, Liu M, Chen Z, Mei K, Yu P, Xie L. Dose-response analysis between hemoglobin A1c and risk of atrial fibrillation in patients with and without known diabetes. PLoS ONE. 2020;15:e0227262.CrossRefPubMedPubMedCentral Zhao H, Liu M, Chen Z, Mei K, Yu P, Xie L. Dose-response analysis between hemoglobin A1c and risk of atrial fibrillation in patients with and without known diabetes. PLoS ONE. 2020;15:e0227262.CrossRefPubMedPubMedCentral
16.
go back to reference Aune D, Feng T, Schlesinger S, Janszky I, Norat T, Riboli E. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. J Diabetes Complications. 2018;32:501–11.CrossRefPubMed Aune D, Feng T, Schlesinger S, Janszky I, Norat T, Riboli E. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. J Diabetes Complications. 2018;32:501–11.CrossRefPubMed
17.
go back to reference Seyed Ahmadi S, Svensson A-M, Pivodic A, Rosengren A, Lind M. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovasc Diabetol. 2020;19:9.CrossRefPubMedPubMedCentral Seyed Ahmadi S, Svensson A-M, Pivodic A, Rosengren A, Lind M. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovasc Diabetol. 2020;19:9.CrossRefPubMedPubMedCentral
18.
go back to reference Nathan DM, on behalf of the International Expert Committee. International Expert Committee Report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:e160–0.CrossRef Nathan DM, on behalf of the International Expert Committee. International Expert Committee Report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:e160–0.CrossRef
19.
go back to reference Gudul NE, Karabag T, Sayin MR, Bayraktaroglu T, Aydin M. Atrial conduction times and left atrial mechanical functions and their relation with diastolic function in prediabetic patients. Korean J Intern Med. 2017;32:286–94.CrossRefPubMed Gudul NE, Karabag T, Sayin MR, Bayraktaroglu T, Aydin M. Atrial conduction times and left atrial mechanical functions and their relation with diastolic function in prediabetic patients. Korean J Intern Med. 2017;32:286–94.CrossRefPubMed
20.
go back to reference Lee SS, Ae Kong K, Kim D, Lim Y-M, Yang P-S, Yi J-E, et al. Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea. Eur Heart J. 2017;38:2599–607.CrossRefPubMed Lee SS, Ae Kong K, Kim D, Lim Y-M, Yang P-S, Yi J-E, et al. Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea. Eur Heart J. 2017;38:2599–607.CrossRefPubMed
21.
go back to reference Li D, Liu Y, Hidru TH, Yang X, Wang Y, Chen C, et al. Protective effects of Sodium-glucose transporter 2 inhibitors on Atrial Fibrillation and Atrial Flutter: a systematic review and Meta- analysis of Randomized Placebo-controlled trials. Front Endocrinol. 2021;12:619586.CrossRef Li D, Liu Y, Hidru TH, Yang X, Wang Y, Chen C, et al. Protective effects of Sodium-glucose transporter 2 inhibitors on Atrial Fibrillation and Atrial Flutter: a systematic review and Meta- analysis of Randomized Placebo-controlled trials. Front Endocrinol. 2021;12:619586.CrossRef
22.
go back to reference Pandey AK, Okaj I, Kaur H, Belley-Cote EP, Wang J, Oraii A, et al. Sodium‐glucose Co‐Transporter inhibitors and Atrial Fibrillation: a systematic review and Meta‐analysis of Randomized controlled trials. J Am Heart Assoc. 2021;10:e022222.CrossRefPubMedPubMedCentral Pandey AK, Okaj I, Kaur H, Belley-Cote EP, Wang J, Oraii A, et al. Sodium‐glucose Co‐Transporter inhibitors and Atrial Fibrillation: a systematic review and Meta‐analysis of Randomized controlled trials. J Am Heart Assoc. 2021;10:e022222.CrossRefPubMedPubMedCentral
23.
go back to reference Abu-Qaoud MR, Kumar A, Tarun T, Abraham S, Ahmad J, Khadke S, et al. Impact of SGLT2 inhibitors on AF Recurrence after catheter ablation in patients with type 2 diabetes. JACC Clin Electrophysiol. 2023;9:2109–18.CrossRefPubMed Abu-Qaoud MR, Kumar A, Tarun T, Abraham S, Ahmad J, Khadke S, et al. Impact of SGLT2 inhibitors on AF Recurrence after catheter ablation in patients with type 2 diabetes. JACC Clin Electrophysiol. 2023;9:2109–18.CrossRefPubMed
24.
go back to reference Bohne LJ, Johnson D, Rose RA, Wilton SB, Gillis AM. The Association between Diabetes Mellitus and Atrial Fibrillation: clinical and mechanistic insights. Front Physiol. 2019;10:135.CrossRefPubMedPubMedCentral Bohne LJ, Johnson D, Rose RA, Wilton SB, Gillis AM. The Association between Diabetes Mellitus and Atrial Fibrillation: clinical and mechanistic insights. Front Physiol. 2019;10:135.CrossRefPubMedPubMedCentral
25.
go back to reference Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. Aggressive risk factor reduction study for Atrial Fibrillation and implications for the outcome of ablation. J Am Coll Cardiol. 2014;64:2222–31.CrossRefPubMed Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. Aggressive risk factor reduction study for Atrial Fibrillation and implications for the outcome of ablation. J Am Coll Cardiol. 2014;64:2222–31.CrossRefPubMed
26.
go back to reference Donnellan E, Aagaard P, Kanj M, Jaber W, Elshazly M, Hoosien M, et al. Association between Pre-ablation Glycemic Control and outcomes among patients with diabetes undergoing Atrial Fibrillation ablation. JACC Clin Electrophysiol. 2019;5:897–903.CrossRefPubMed Donnellan E, Aagaard P, Kanj M, Jaber W, Elshazly M, Hoosien M, et al. Association between Pre-ablation Glycemic Control and outcomes among patients with diabetes undergoing Atrial Fibrillation ablation. JACC Clin Electrophysiol. 2019;5:897–903.CrossRefPubMed
27.
go back to reference Stout KM, Tandon H, Adomako R, Schleifer JW, Payne J, Easley A, et al. Poor glycemic control in diabetic patients increases the risk of recurrent atrial arrhythmia and cardiovascular hospitalizations among morbidly obese patients undergoing atrial fibrillation ablation. Eur Heart J. 2021;42(Supplement_1):ehab7240513.CrossRef Stout KM, Tandon H, Adomako R, Schleifer JW, Payne J, Easley A, et al. Poor glycemic control in diabetic patients increases the risk of recurrent atrial arrhythmia and cardiovascular hospitalizations among morbidly obese patients undergoing atrial fibrillation ablation. Eur Heart J. 2021;42(Supplement_1):ehab7240513.CrossRef
28.
go back to reference Lu Z-H, Liu N, Bai R, Yao Y, Li S-N, Yu R-H, et al. HbA1c levels as predictors of ablation outcome in type 2 diabetes mellitus and paroxysmal atrial fibrillation. Herz. 2015;40:130–6.CrossRefPubMed Lu Z-H, Liu N, Bai R, Yao Y, Li S-N, Yu R-H, et al. HbA1c levels as predictors of ablation outcome in type 2 diabetes mellitus and paroxysmal atrial fibrillation. Herz. 2015;40:130–6.CrossRefPubMed
29.
go back to reference Potpara T, Dagres N, Arbelo E, Bax JJ, Boriani G, Castella M et al. The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Potpara T, Dagres N, Arbelo E, Bax JJ, Boriani G, Castella M et al. The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC).
30.
go back to reference Kuck K-H, Brugada J, Fürnkranz A, Metzner A, Ouyang F, Chun KRJ, et al. Cryoballoon or Radiofrequency ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016;374:2235–45.CrossRefPubMed Kuck K-H, Brugada J, Fürnkranz A, Metzner A, Ouyang F, Chun KRJ, et al. Cryoballoon or Radiofrequency ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016;374:2235–45.CrossRefPubMed
31.
go back to reference Xia Y, Li X-F, Liu J, Yu M, Fang P-H, Zhang S. The influence of metabolic syndrome on atrial fibrillation recurrence: five-year outcomes after a single cryoballoon ablation procedure. J Geriatr Cardiol. 2021;18:1019–28.PubMedPubMedCentral Xia Y, Li X-F, Liu J, Yu M, Fang P-H, Zhang S. The influence of metabolic syndrome on atrial fibrillation recurrence: five-year outcomes after a single cryoballoon ablation procedure. J Geriatr Cardiol. 2021;18:1019–28.PubMedPubMedCentral
32.
go back to reference Ichihara N, Miyazaki S, Kuroi A, Hachiya H, Nakamura H, Taniguchi H, et al. Impact of pulmonary vein isolation on Superior Vena Cava potentials with a second-generation Cryoballoon. J Cardiovasc Electrophysiol. 2015;26:1321–6.CrossRefPubMed Ichihara N, Miyazaki S, Kuroi A, Hachiya H, Nakamura H, Taniguchi H, et al. Impact of pulmonary vein isolation on Superior Vena Cava potentials with a second-generation Cryoballoon. J Cardiovasc Electrophysiol. 2015;26:1321–6.CrossRefPubMed
33.
go back to reference Kawai S, Okahara A, Tokutome M, Tobushi T, Mukai Y. Real-time superior vena cava isolation during cryoballoon ablation of the right pulmonary veins: a case report. HeartRhythm Case Rep. 2020;6:922–4.CrossRefPubMedPubMedCentral Kawai S, Okahara A, Tokutome M, Tobushi T, Mukai Y. Real-time superior vena cava isolation during cryoballoon ablation of the right pulmonary veins: a case report. HeartRhythm Case Rep. 2020;6:922–4.CrossRefPubMedPubMedCentral
Metadata
Title
Association between baseline glycated hemoglobin level and atrial fibrillation recurrence following cryoballoon ablation among patients with and without diabetes
Authors
Zheng Chen
Ruixin Zhang
Xinlin Zhang
Wei Xu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2024
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-024-03784-4

Other articles of this Issue 1/2024

BMC Cardiovascular Disorders 1/2024 Go to the issue